공지
- [ 2024-05-10 ] 공용위원회 심의·협약 대상 및 비용 납부 안내 규정 공고
- [ 2024-05-07 ] 2024년 한국의료윤리학회 춘계학술대회 개최 안내(5/25(토))
- [ 2024-04-30 ] [2024년 생명윤리정책연구 자유공모 지원사업] 최종 선정과제 안내
- [ 2024-04-30 ] 『생명윤리 언론동향 브리프』 제13호 발간 안내
- [ 2024-04-30 ] 2024년 상반기(5월) 유전자검사기관 종사자 교육 안내
관련 논문
*정책원 미소장 자료이며 관련 논문 소개 게시판입니다. 게시물 관련링크를 눌러 소속기관에서 열람가능한지 확인해주시기 바랍니다.
lib@nibp.kr
글 수 869
| 발행년 : | 2018 |
|---|---|
| 구분 : | 국내학술지 |
| 학술지명 : | 신경정신의학 |
| 관련링크 : | http://www.riss.kr/link?id=A105304264 |
알츠하이머 치매 약물치료의 현황과 미래
= Past and Future of Drug Treatments for Alzheimer s Disease
- 저자[authors] 김성윤
- 학술지명[periodical name] 신경정신의학
- 권호사항[Volume/Issue] Vol.57No.1[2018]
- 발행처[publisher] 대한신경정신의학회
- 자료유형[Document Type] 학술저널
- 수록면[Pagination] 30-42
- 언어[language] Korean
- 발행년[Publication Year] 2018
- KDC[Korean Decimal Classification] 513.85
- 주제어[descriptor] 알츠하이머 치매,약물치료,아밀로이드,타우,콜린 분해효소 억제제
초록[abstracts]
[This study reviews evidence for the use of acetyl- choline esterase inhibitors (AChEIs) in treating Alzheimer s patients for the past decades. Even though large number of clinical trials have been conducted to prove the efficacy of these drugs in various clinical situations, questions remain to be answered due to the use of heterogeneous subject population, trial designs, and measurement tools in these studies. Many drugs with unproven clinical benefits, including vitamins, ginko biloba extracts, anti- inflammatory agents, estrogen hormone, and statins, are commonly prescribed in real- world settings for dementia patients. Despite the lack of clinical benefits statistically proven by clinical trials or meta- analyses, anecdotal dramatic improvements in some patients may foster such practices. A further look into why some patients benefit from these medications, while other don t, may shed light on future individually tailored medicine for dementia patients. This study provides a brief review of currently existing immuno- therapeutics in the hope that we can learn from the failures of the amyloid- based active and passive immunization. Issues that we need to address for the successful development of new anti- AD drugs include : 1) the brain pathology precedes clinical symptoms by several decades, 2) we need biological markers that reliably reflect cognitive or functional impairment of AD patients, and 3) we need more detailed and plausible explanations for our brain immune responses and neurodegenerative changes.]
목차[Table of content]
서론 알츠하이머 치매의 인지증상 개선을 위한 약물 임상시험 근거가 미약하나 현실적으로 사용되고 있는 약물들 임상시험이 진행 중인 실험적 약물들 결론 Notes References
(†04522) 서울 특별시 중구 남대문로 113 DB다동빌딩 5층
TEL : 02-737-8970 (기획운영팀)
Copyright (c)KONIBP All Right Reserved.
Copyright (c)KONIBP All Right Reserved.
2sisstore
